Back to search results

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of California San Diego, La Jolla, California, United States

    Contact: Study coordinator (Elizabeth Elmes) · lelmes@health.ucsd.edu · 858-822-6185
    Contact: Principal Investigator (Rana McKay, MD)

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

    Contact: Study coordinator (Maria Burton) · mariburt@iu.edu · 317-278-2535
    Contact: Principal Investigator (Jennifer King, MD)

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Lynne Mitchell, MS CRM, MA BS) · lynne.mitchell@wustl.edu
    Contact: Principal Investigator (Melissa Reimers, MD)

  • Columbia University Irving Medical Center, New York, New York, United States

    Contact: Study coordinator (Zach Leid) · zl3559@cumc.columbia.edu · 212-305-0787
    Contact: Study coordinator (Clinical Protocol and Data Management Office) · chemorx@lists.cumc.columbia.edu · 212-305-0787
    Contact: Principal Investigator (Karie Runcie, MD)
Study leads

  • Karie Runcie, MD

    Principal Investigator

    Columbia University

View source on ClinicalTrials.gov(opens in a new tab)